We have entered a new economic age of more moderate growth expectations while faced with an aging population crisis that is threatening to bankrupt us if nothing is done to adapt.
Health systems around the world are recognizing that the way of the future will be a shift to team-based care models that:
- Leverage technology, based upon best available evidence;
- Focus on outcomes;
- Integrate across care settings; and,
- Deliver the right care, at the right time, in the right location
The challenge is enabling this transformation in an uncertain environment where new — often non-traditional — players are entering the market and forming new partnerships and models. In a convergent marketplace where the lines between traditional health and life sciences ecosystem players are blurring, companies must be agile, innovative and daring in order to ensure the sustainability of their business.
KPMG’s Canadian Life Science practice is dedicated to assisting businesses of all sizes from biotechnology start-ups to large multinational pharmaceutical, medical device and health technology companies. We take an enterprise-wide view to business transformation by assisting clients from strategy through to execution. KPMG’s proprietary methodologies connect business model design (strategy) and operating model implementation (execution). Further, KPMG holds a differentiated position in the marketplace offering clients a wide range of implementation services through our deal advisory and risk consulting capabilities. The end result is a client engagement where strategy, business model and operations are all in sync.